Alnylam Pharmaceuticals, Inc. (ALNY) Monday said first-quarter loss narrowed to $9.0 million or $0.15 per share from $11.4 million or $0.25 per share in the same period last year.
On average, seven analysts polled by Thomson Reuters expected the company to report a loss of $0.29 per share for the quarter. Analysts' estimates typically exclude special items.
Revenues totaled $18.6 million, down from $20.6 million last year. Analysts expected revenues of $15.56 million.
Operating expenses decreased to $28.45 million from $31.48 million last year.
For comments and feedback: editorial@rttnews.com